PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-2.12%
Revenue decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
-8.45%
Cost reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive advantage potential.
21.56%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.63%. Joel Greenblatt would investigate competitive advantages.
24.18%
Margin change of 24.18% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
-68.16%
R&D reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
29.49%
G&A change of 29.49% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
-0.68%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-62.02%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
6.28%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.06%. Jim Chanos would check for waste.
-2.66%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is -0.51%. Seth Klarman would investigate advantages.
-76.74%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
27.58%
D&A growth while Drug Manufacturers - Specialty & Generic reduces D&A. Peter Lynch would examine asset strategy.
630.78%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.45%. Joel Greenblatt would investigate advantages.
642.25%
EBITDA margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.02%. Joel Greenblatt would investigate advantages.
123.81%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.43%. Joel Greenblatt would investigate advantages.
124.33%
Operating margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.45%. Joel Greenblatt would investigate advantages.
23.48%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.37%. Jim Chanos would check for issues.
40094.44%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.14%. Joel Greenblatt would investigate advantages.
40963.06%
Margin change of 40963.06% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
67.73%
Tax expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.06%. Jim Chanos would check for issues.
645.04%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.97%. Joel Greenblatt would investigate advantages.
661.14%
Margin change of 661.14% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
22200.00%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.12%. Joel Greenblatt would investigate advantages.
22200.00%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.12%. Joel Greenblatt would investigate advantages.
5.52%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would check for issues.
6.15%
Diluted share change of 6.15% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.